Instead of traditional metrics, a useful gauge for biotech valuation is the number of years it would take for large pharma's free cash flow to acquire the entire SMIDCAP biotech sector. Currently under four years, this indicates valuations are not at the extreme highs seen in 2020 (over five years).

The extreme pricing of some new drugs leads analysts to question the valuation logic. One theory is that companies determine a revenue goal, then simply divide it by the eligible patient population to arrive at a price, rather than basing it on R&D costs or clinical value.

Despite a massive stock increase and a high burn rate, Moderna has surprisingly not raised capital, defying the biotech axiom to "raise money when you can." This suggests a deliberate strategy, possibly to let the valuation stabilize after a potential short squeeze before pricing an offering, despite having years of cash runway.

Eli Lilly's deal chief revealed that even premium acquisition offers are frequently rebuffed by public biotech companies without negotiation. This highlights a significant valuation gap where biotech boards believe their assets are worth far more than what even well-capitalized buyers like Lilly are willing to pay, stalling potential M&A activity.

The current market prefers funding drugs for clinically validated targets, reducing 'biology risk'. However, this floods popular targets with dozens of competitors, creating immense 'commercial risk' where only one or two can truly succeed in a crowded field, a potentially worse gamble.

Recent biotech deals are setting new valuation records for companies at specific early stages: preclinical (AbbVie/Capstan, ~$2B), Phase 1 (J&J/Halda, $3B), and pre-Phase 3 (Novartis/Abitivi, $12B). This signals intense demand for de-risked innovation well before late-stage data is available.

Despite significant stock price increases (e.g., 3-4x for some names), the current biotech rally is not a sign of an overheated market. Many small-cap companies are still trading at a fraction of their potential value based on their pipelines, suggesting the rally is a recovery from deeply distressed, sub-cash valuations.

While mRNA vaccines were a triumph, mRNA therapeutics have never been approved. Therapeutics require higher protein production and precise cellular targeting, a far greater technical challenge than the broad immune response stimulated by vaccines. This distinction is a major blind spot for the public.

Sanofi's $2.2 billion acquisition of Dynavax at a 39% premium highlights the high value placed on companies with approved products and a promising pipeline. This demonstrates the willingness of major pharmaceutical companies to pay significantly above market price to secure de-risked assets and expand strategic portfolios like vaccines.